This phase II clinical trial with safety follow-up is designed to evaluate the efficacy and safety of Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) administered via intracavernous injection in patients with erectile dysfunction after radical prostatectomy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Tumor Marker Levels
Timeframe: Baseline and annually for up to 5 years after enrollment in the long-term follow-up study.
Serious Adverse Events
Timeframe: From enrollment in the long-term follow-up study through 5 years of follow-up.
New Cancer Development
Timeframe: From enrollment in the long-term follow-up study through 5 years of follow-up.
Prostate Cancer Recurrence
Timeframe: From enrollment in the long-term follow-up study through 5 years of follow-up.